These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21806775)

  • 1. Spironolactone is more effective than eplerenone at lowering blood pressure in patients with primary aldosteronism.
    Bloch MJ; Basile JN
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):629-31. PubMed ID: 21806775
    [No Abstract]   [Full Text] [Related]  

  • 2. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
    Parthasarathy HK; Ménard J; White WB; Young WF; Williams GH; Williams B; Ruilope LM; McInnes GT; Connell JM; MacDonald TM
    J Hypertens; 2011 May; 29(5):980-90. PubMed ID: 21451421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
    Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
    Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
    Manolis AA; Manolis TA; Melita H; Manolis AS
    Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.
    Fourkiotis V; Vonend O; Diederich S; Fischer E; Lang K; Endres S; Beuschlein F; Willenberg HS; Rump LC; Allolio B; Reincke M; Quinkler M;
    Eur J Endocrinol; 2013 Jan; 168(1):75-81. PubMed ID: 23033260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
    Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
    Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
    Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
    Pechère-Bertschi A; Herpin D; Lefebvre H
    Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-On Use of Eplerenone Is Effective for Lowering Home and Ambulatory Blood Pressure in Drug-Resistant Hypertension.
    Eguchi K; Kabutoya T; Hoshide S; Ishikawa S; Kario K
    J Clin Hypertens (Greenwich); 2016 Dec; 18(12):1250-1257. PubMed ID: 27296360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.
    Ichikawa S; Tajima Y; Sakamaki T; Matsuo H; Kogure M; Hirano Y; Yagi S; Murata K
    Jpn Circ J; 1984 Nov; 48(11):1184-96. PubMed ID: 6502914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
    Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
    Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
    Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Higuchi H; Sai S; Nakatsukasa T; Sugano A; Baba M; Obara K; Aonuma K
    Heart Vessels; 2019 Feb; 34(2):279-289. PubMed ID: 30203391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.
    Carey RM
    Curr Cardiol Rep; 2016 Oct; 18(10):97. PubMed ID: 27566330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
    Weinberger MH; Roniker B; Krause SL; Weiss RJ
    Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
    Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
    Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.